NEWS May 4, 2013

Research companies from USA and Isarel put down roots in Sweden

November 4, 2013 Download PDF In the middle of the acquisition process the CEOs of EpiCept Corporation and Immune Pharmaceuticals Ltd. are meeting in Sweden to discuss EpiCept’s listing on the stock exchange in Stockholm after the merger. But the Israeli company’s CEO is rather taken by Sweden and his goal now is to expand […]

Keep Reading

NEWS April 23, 2013

“Can Israel Become the Next Biotech Startup Nation?”

Immune Pharmaceuticals CEO to Chair BIO International Panel “Can Israel Become the Next Biotech Startup Nation?” April 23, 2013 HERZLIYA-PITUACH, Israel /PRNewswire/ — Immune Pharmaceuticals Ltd. (“Immune”), a privately held Israeli company, announced today that the company’s CEO Daniel Teper is the moderator of this morning’s BIO International Convention breakout session “Can Israel Become the Next BioTech […]

Keep Reading

NEWS February 25, 2013

Immune Pharmaceuticals starts a phase II clinical trial in Ulcerative Colitis- The Marker

February 25, 2013 Immune Pharma, which plans to merge with Epicept, initiates the clinical trial after receiving the approval of the Ministry of Health   Immune Pharmaceuticals, which plans to merge with Epicept, began Phase II Clinical Trials with Bertilimumab, a new drug developped for the treatment of Ulcerative Colitis after receiving the approval […]

Keep Reading

NEWS December 6, 2012

BioTuesday: “Immune-EpiCept to get multiple clinical shots on goal”

December 6, 2012 The Immune-Epicept merger was featured on, a weekly highlight of Global Healthcare. The feature covers that the proposed union of closely held Immune Pharmaceuticals of Israel and EpiCept (NASDAQ OMX Stockholm, OTCQX: EPCT) will create a combined company focused on antibody therapeutics for cancer and inflammation, with four products in the […]

Keep Reading

NEWS May 24, 2012

Immune Pharmaceuticals, Yeda Partner on Her3 Antibody Development

May 24, 2012 Download PDF   Immune Pharmaceuticals established a broad collaboration with the Weizmann Institute of Science’s technology transfer company Yeda, focused on developing antibody therapeutics targeting Her3, an epidermal growth factor family target that is overexpressed in some patients with gastric, head and neck, ovarian, and breast cancer. Through the new collaboration Immune […]

Keep Reading

NEWS December 11, 2011

Here Come the NanomAbs

Bio Israel Life Sciences On-Line – December 11, 2011 at 7:56 am   A new monoclonal antibody-based drug development company brings a fresh technological approach and ambitious business model to the Israeli biotech scene. Scientists for years have been looking for ways to enhance the specificity with which antibodies recognize antigens, their stability in […]

Keep Reading